Sign up
PYPD

PolyPid (NASDAQ: PYPD)

Healthcare · Biotechnology

$6.56+0.02 (+0.31%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. PYPD rose 0.31% in the Nov 18 session to $6.56, which is 0.6% below its 52-week high of $6.60. Short interest is 3.60% of float with a 5.99% borrow fee. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $13.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 59.6 (overbought above 70, oversold below 30)

Trend—

—

Short interest3.6% of float

FINRA settlement Oct 30, 2026

PYPD price chart

Price $6.56 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$6.60Nov 18, 2026 session
Previous close
$6.54Nov 17, 2026 close
Day range
$6.46 – $6.80Nov 18, 2026 session
52-week range
$3.60 – $6.60Through Nov 18, 2026
Volume
306.10KNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$109.48M
P/E (TTM)negative earnings —
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

PYPD · nasdaq · USD

Last completed session: Nov 18, 2026

Split-adjusted · volume in shares

November 2026 · 13 completed sessions
DateOpenHighLowCloseChangeVolume
6.606.806.466.56+0.02+0.30581%303,793
Open 6.60High 6.80Low 6.46
6.216.576.126.54+0.39+6.341463%772,608
Open 6.21High 6.57Low 6.12
6.236.256.036.15−0.11−1.757188%211,832
Open 6.23High 6.25Low 6.03
6.586.586.036.26−0.14−2.1875%193,158
Open 6.58High 6.58Low 6.03
6.7356.9686.336.40−0.20−3.030303%189,564
Open 6.735High 6.968Low 6.33
6.687.156.186.60+0.29+4.59588%424,696
Open 6.68High 7.15Low 6.18
6.246.355.906.31+0.07+1.121795%153,681
Open 6.24High 6.35Low 5.90
6.186.486.0556.24+0.10+1.628664%263,672
Open 6.18High 6.48Low 6.055
5.716.145.52016.14+0.47+8.289242%185,613
Open 5.71High 6.14Low 5.5201
5.825.935.365.67−0.15−2.57732%242,045
Open 5.82High 5.93Low 5.36
5.565.895.565.82+0.36+6.593407%170,969
Open 5.56High 5.89Low 5.56
5.745.745.325.46+0.04+0.738007%100,487
Open 5.74High 5.74Low 5.32
5.5485.695.275.42+0.03+0.556586%205,798
Open 5.548High 5.69Low 5.27

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide89Storm Surge—
Squeeze27Idle—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
1Buy
0Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$13.00
Average$13.00
High$13.00

As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FCITADEL ADVISORS LLCIncreased position$253.0K13F filing
13FRENAISSANCE TECHNOLOGIES LLCOpened position$81.5K13F filing
13FCITADEL ADVISORS LLCOpened position$46.5K13F filing
13FCITADEL ADVISORS LLCClosed position$013F filing
13FCITADEL ADVISORS LLCIncreased position$46.4K13F filing
13FCITADEL ADVISORS LLCOpened position$28.6K13F filing
13FMILLENNIUM MANAGEMENT LLCClosed position$013F filing
13FRENAISSANCE TECHNOLOGIES LLCClosed position$013F filing
13FMILLENNIUM MANAGEMENT LLCReduced position$7.6K13F filing
13FRENAISSANCE TECHNOLOGIES LLCOpened position$1113F filing
All smart-money activity →

News and press releases

All PYPD news →

Company profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in

CEO
—
Headquarters
Petah Tikva, Israel
Employees
69
IPO date
Jun 26, 2020
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.